PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1755791
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1755791
Radiotheranostics Market Growth, Size, Trends Analysis - By Radioisotope, By Approach, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Radiotheranostics Market Introduction and Overview
According to SPER market research, 'Global Radiotheranostics Market Size- By Radioisotope, By Approach, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Radiotheranostics Market is predicted to reach 35.22 billion by 2034 with a CAGR of 13.74%.
Radiotheranostics is a new area in medicine that merges diagnosis and treatment using radiopharmaceuticals. It uses radiotracers, which are molecules with radioactive isotopes, to diagnose and treat diseases at the same time. Techniques like positron emission tomography (PET) or single-photon emission computed tomography (SPECT) are used to identify specific targets in the body, offering precise and personalized diagnosis by detailing the disease's location and extent. The treatment entails providing radiation therapy to the illness site.
Restraints: The high cost of radiopharmaceuticals and radiotheranostics treatments can cause problems for patients and healthcare professionals alike. The cost-effectiveness and affordability of these technologies need to be addressed in order to ensure further adoption and market expansion.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Radioisotope, By Approach, By Application
Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered Novartis AG, Bayer AG, Progenics Pharmaceuticals, Inc. (Lantheus), Telix Pharmaceuticals Limited, ITM Radiopharma, Life Molecular Imaging, RadioMedix, IsoTherapeutics Group, LLC, Q BioMed Inc, Nordic Nanovector ASA.
Global Radiotheranostics Market Segmentation:
By Radioisotope: Based on the Radioisotope, Global Radiotheranostics Market is segmented as; Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90.
By Approach: Based on the Approach, Global Radiotheranostics Market is segmented as; Targeted Therapeutic, Targeted Diagnostic.
By Application: Based on the Application, Global Radiotheranostics Market is segmented as; Oncology, Non-oncology.
Table of Contents
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
- 2.2. Market size estimation
3. Executive Summary
4. Market Dynamics
5. Market variable and outlook
6. Competitive Landscape
7. Global Radiotheranostics Market, By Radioisotope (USD Million) 2021-2034
8. Global Radiotheranostics Market, By Approach (USD Million) 2021-2034
9. Global Radiotheranostics Market, By Application (USD Million) 2021-2034
10. Global Radiotheranostics Market, (USD Million) 2021-2034
11. Global Radiotheranostics Market, By Region, (USD Million) 2021-2034
12. Company Profile
13. Conclusion
14. List of Abbreviations
15. Reference Links
